[see Use in Specific Populations (8.5, 8.6), Clinical Pharmacology (12.3)]. Data are not available for the use of Valacyclovir hydrochloride tablets in pediatric patients with a creatinine clearance <50 mL/min/1.73 m2.
|Indications||Normal Dosage Regimen||Creatinine Clearance||(mL/min)|
|(Creatinine Clearance ≥50 mL/min)||30-49||10-29||<10|
|Cold sores ( Herpes labialis ) Do not exceed 1 day of treatment .||Two 2 gram doses taken 12 hours apart||Two 1 gram doses taken 12 hours apart||Two 500 mg doses taken 12 hours apart||500 mg single dose|
|Genital herpes : Initial episode||1 gram every 12 hours||no reduction||1 gram every 24 hours||500 mg every 24 hours|
|Genital herpes : Recurrent episode||500 mg every 12 hours||no reduction||500 mg every 24 hours||500 mg every 24 hours|
|Genital herpes : Suppressive therapy|
|Immunocompetent patients||1 gram every 24 hours||no reduction||500 mg every 24 hours||500 mg every 24 hours|
|Alternate dose for immunocompetent patients with ≤9 recurrences/year||500 mg every 24 hours||no reduction||500 mg every 48 hours||500 mg every 48 hours|
|HIV-infected patients||500 mg every 12 hours||no reduction||500 mg every 24 hours||500 mg every 24 hours|
|Herpes zoster||1 gram every 8 hours||1 gram every 12 hours||1 gram every 24 hours||500 mg every 24 hours|
Hemodialysis: Patients requiring hemodialysis should receive the recommended dose of valacyclovir hydrochloride after hemodialysis. During hemodialysis, the half-life of acyclovir after administration of valacyclovir hydrochloride is approximately 4 hours. About one third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session.
Peritoneal Dialysis: There is no information specific to administration of valacyclovir hydrochloride in patients receiving peritoneal dialysis. The effect of chronic ambulatory peritoneal dialysis (CAPD) and continuous arteriovenous hemofiltration/dialysis (CAVHD) on acyclovir pharmacokinetics has been studied. The removal of acyclovir after CAPD and CAVHD is less pronounced than with hemodialysis, and the pharmacokinetic parameters closely resemble those observed in patients with end-stage renal disease (ESRD) not receiving hemodialysis. Therefore, supplemental doses of valacyclovir hydrochloride should not be required following CAPD or CAVHD.
- 500 mg: blue coloured, film-coated, capsule-shaped, biconvex tablets, “CIPLA” debossed on one side and “153” on other.
- 1 gram: blue coloured, film-coated, capsule-shaped, biconvex tablets, with a partial scorebar on both sides, and “CIPLA” debossed on one side and “154” on other.
Valacyclovir hydrochloride is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation [see Adverse Reactions (6.3)] .
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.